OSCR
Oscar Health, Inc.
OSCR has the edge over SKIN overall, supported by stronger fundamentals and lower modeled downside.
SKIN
SkinHealth Systems Inc.
SKIN offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
SKIN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Stable | |
| Strong |
SKIN's balance sheet is currently strong, and its revenue, profitability and cash flow are stable.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
SKIN PE Valuation
SKIN has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over SKIN on the outlook, with more favorable revenue expectations.
SKIN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect SKIN's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over SKIN in the latest year-over-year earnings comparison.
SKIN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.94 | +$2.12 |
| Q2 2026 | -$3.60 | +$1.66 |
| Q1 2026 | -$2.60 | +$5.26 |
SKIN is still losing money, but far less than before: $1.94 per share over the past year, against $99.60 at its worst in early 2022.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over SKIN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
SKIN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $69.2M | -2.1% |
| Q2 2026 | $72.1M | -7.8% |
| Q1 2026 | $64.9M | -6.7% |
| Q4 2025 | $82.4M | -1.3% |
| Q3 2025 | $70.7M | -10% |
| Q2 2025 | $78.2M | -14% |
| Q1 2025 | $69.6M | -15% |
| Q4 2024 | $83.5M | -14% |
SKIN's revenue has slid since its 2023 peak: $69M last quarter, down 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.2% | +16 points |
| Q2 2026 | 5% | +8.4 points |
| Q1 2026 | -2.8% | +15 points |
| Q4 2025 | 0.2% | +8.8 points |
| Q3 2025 | -8.8% | +19 points |
| Q2 2025 | -3.5% | +21 points |
| Q1 2025 | -17% | +3.6 points |
| Q4 2024 | -8.6% | +10 points |
SKIN has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over SKIN on cash flow, with more consistent year-over-year improvement.
SKIN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $11.2M | +16% |
| Q2 2026 | $2.2M | -77% |
| Q1 2026 | -$5.8M | -296% |
| Q4 2025 | $15.1M | -8.2% |
| Q3 2025 | $9.6M | -6.7% |
| Q2 2025 | $9.6M | +63% |
| Q1 2025 | $3M | +$20.1M |
| Q4 2024 | $16.4M | +$21.6M |
SKIN still generates free cash flow, though less than at its 2023 peak: $23M over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
SKIN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +30.3K shares |
| 1 year | +2.6% | +166K shares |
| 3 years | -1.9% | -126K shares |
| 5 years | +1032% | +5.9M shares |
SKIN has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2023 | $30.2M |
| Q4 2022 | $80M |
| Q4 2021 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
SKIN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.8x | Net Cash |
| Q2 2026 | -13.5x | Net Cash |
| Q1 2026 | -21.9x | Net Cash |
| Q4 2025 | -7,050.7x | Net Cash |
SKIN has the edge over OSCR on leverage, with a lower net debt burden relative to earnings.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
SKIN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.9 | Neutral |
| Stochastic | 58.5 | Neutral |
SKIN's weekly RSI is 54 (neutral) and its Stochastic is 59 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SKIN PE vs Healthcare Sector
SKIN has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over SKIN on trend strength, trading above more of its moving averages.
SKIN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.5 | 28% above |
| 20 week MA | $13.6 | 17% above |
| 50 week MA | $18.1 | 12% below |
| 100 week MA | $25.2 | 37% below |
| 200 week MA | $64.3 | 75% below |
SKIN has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 75% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over SKIN on returns for 2026, with the stronger performance.
SKIN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $204.2 | $223.0 | +9.2% |
| 2021 | $223.0 | $463.0 | +108% |
| 2022 | $463.0 | $180.8 | -61% |
| 2023 | $180.8 | $62.2 | -66% |
| 2024 | $62.2 | $32.4 | -48% |
| 2025 | $32.4 | $29.2 | -9.9% |
| 2026 YTD | $29.2 | $16.0 | -45% |
SKIN has finished four years in a row lower, and it's down 45% so far in 2026.